KIT and glioblastoma: c-KIT, VEGFR2 and PDGFRα have previously been found to be amplified in 15–33% of primary glioblastomas [20], [41] and amplification of c-KIT and PDGFRα to be associated with poor survival of glioblastoma patients [21].